ArticleEuropean urology oncology2025
The Burden of Genitourinary Malignancies in Southeast Asia from 1990 to 2021.
Article in European urology oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
BACKGROUND AND
objectiveThe global burden of genitourinary (GU) cancers is rising; yet, the specific burden on the diverse population of 700 million in Southeast Asia (SEA) remains poorly understood. This study presents the most updated trends in the incidence and mortality of bladder, kidney, prostate, and testicular cancer patients across SEA from 1990 to 2021.
methodsData from the Global Burden of Disease 2021 database were analyzed for the incidence, deaths, and age-standardized rates by sex and age of patients with four major GU cancers across 11 SEA countries from 1990 to 2021. KEY FINDINGS AND LIMITATIONS: GU cancer incidence and mortality in SEA primarily increased from 1990 to 2021. Kidney cancer showed the greatest rise in incidence and deaths for both sexes, while prostate cancer had the largest absolute increase in male incidence and mortality. In 2021, Brunei had the highest age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of kidney cancer for both sexes. Singapore had the highest prostate cancer ASIR, with the incidence rising in all countries except in Laos, and the Philippines recorded the highest ASMR. For bladder cancer, Thailand and Brunei recorded the highest ASIR for males and females, respectively, while Malaysia had the highest male ASMR and Brunei the female ASMR. Testicular cancer ASIR was highest in Singapore; however, ASMR in Singapore decreased over the study period, but increased or remained stable across the region. CONCLUSIONS AND CLINICAL IMPLICATIONS: Broadly, the rising age-standardized incidence of GU cancers in SEA reflects not only the evolving patterns of modifiable and nonmodifiable risk factors, but also the development of cancer diagnostic systems and improvements in reporting infrastructure. For many SEA countries, these increases warrant enhanced resource allocation for cancer system strengthening, to support timely diagnosis and equitable access to affordable, effective treatment. Regional and international collaboration is essential to promote equity in access to cancer care in SEA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.